Tvardi Therapeutics Inc. (TVRD)
NASDAQ: TVRD
· Real-Time Price · USD
40.23
2.86 (7.65%)
At close: Oct 03, 2025, 3:59 PM
40.55
0.80%
After-hours: Oct 03, 2025, 04:21 PM EDT
7.65% (1D)
| Bid | 34.51 |
| Market Cap | 377.22M |
| Revenue (ttm) | 6.58M |
| Net Income (ttm) | -20.89M |
| EPS (ttm) | -2.25 |
| PE Ratio (ttm) | -17.88 |
| Forward PE | -9.76 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 40.55 |
| Volume | 58,112 |
| Avg. Volume (20D) | 40,250 |
| Open | 39.24 |
| Previous Close | 37.37 |
| Day's Range | 37.94 - 41.00 |
| 52-Week Range | 8.14 - 41.00 |
| Beta | 0.24 |
| Ex-Dividend Date | n/a |
About TVRD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TVRD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TVRD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+9.07%
Tvardi Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+14.78%
Tvardi Therapeutics shares are trading higher after the company announced it completed the enrollment for its phase 2 clinical trial of TTI-101.
2 months ago · businesswire.com
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceHOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...